Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin for coronary atherosclerosis in T2DM
NCT03602638Phase 4Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) and Coronary atherosclerosis (CAD) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Coronary calcification score at 18 months. Status: unknown.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)Coronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT03602638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602638.